[go: up one dir, main page]

AR121243A1 - Composición para prevenir o tratar enfermedades pulmonares que comprenden hialuronano y proteína 1 de enlace de proteoglicano - Google Patents

Composición para prevenir o tratar enfermedades pulmonares que comprenden hialuronano y proteína 1 de enlace de proteoglicano

Info

Publication number
AR121243A1
AR121243A1 ARP210100261A ARP210100261A AR121243A1 AR 121243 A1 AR121243 A1 AR 121243A1 AR P210100261 A ARP210100261 A AR P210100261A AR P210100261 A ARP210100261 A AR P210100261A AR 121243 A1 AR121243 A1 AR 121243A1
Authority
AR
Argentina
Prior art keywords
protein
hapln1
lung diseases
hyaluronan
composition
Prior art date
Application number
ARP210100261A
Other languages
English (en)
Inventor
Dae Kyong Kim
Yongwei Piao
Ji Min Jang
Dan Zhou
So Yoon Yun
Bo Kyung Park
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of AR121243A1 publication Critical patent/AR121243A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica para la prevención o el tratamiento de enfermedades pulmonares, que comprende: por lo menos uno seleccionado del grupo que consiste en la proteína HAPLN1 (proteína 1 de enlace de hialuronano y proteoglicano), un gen que codifica para la proteína HAPLN1, y un agente eficaz para la promoción de la expresión o la activación de las funciones de la proteína o el gen HAPLN1 como componente activo. Reivindicación 5: Una composición de alimentos funcionales para la salud para la mejora o la prevención de enfermedades pulmonares, que comprende: por lo menos uno seleccionado del grupo que consiste en la proteína HAPLN1 (proteína 1 de enlace de hialuronano y proteoglicano), un gen que codifica para la proteína HAPLN1, y un agente eficaz para la promoción de la expresión o la activación de las funciones de la proteína o el gen HAPLN1 como componente activo. Reivindicación 10: El método de acuerdo con la reivindicación 8, en el que las enfermedades pulmonares son una o más seleccionadas del grupo que consiste en bronquitis crónica, asma, enfisema y enfermedad pulmonar obstructiva crónica (EPOC).
ARP210100261A 2020-02-03 2021-02-01 Composición para prevenir o tratar enfermedades pulmonares que comprenden hialuronano y proteína 1 de enlace de proteoglicano AR121243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200012742A KR102166453B1 (ko) 2020-02-03 2020-02-03 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
AR121243A1 true AR121243A1 (es) 2022-05-04

Family

ID=72882981

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100261A AR121243A1 (es) 2020-02-03 2021-02-01 Composición para prevenir o tratar enfermedades pulmonares que comprenden hialuronano y proteína 1 de enlace de proteoglicano

Country Status (17)

Country Link
US (1) US12268728B2 (es)
EP (1) EP3887525B1 (es)
JP (1) JP7329877B2 (es)
KR (1) KR102166453B1 (es)
CN (1) CN115427576B (es)
AR (1) AR121243A1 (es)
AU (1) AU2021216358A1 (es)
BR (1) BR112022015361A2 (es)
CA (1) CA3166146A1 (es)
CL (1) CL2022002067A1 (es)
CO (1) CO2022011135A2 (es)
ES (1) ES2964715T3 (es)
IL (1) IL294952A (es)
MX (1) MX2022009544A (es)
PE (1) PE20221663A1 (es)
TW (1) TWI792171B (es)
WO (1) WO2021158000A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102166453B1 (ko) 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
KR102284800B1 (ko) 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법
KR102678583B1 (ko) * 2021-05-31 2024-06-27 중앙대학교 산학협력단 Hapln1을 포함하는 혈관질환 예방 또는 치료용 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584462Y2 (ja) 1980-10-13 1983-01-25 古賀産業株式会社 海苔「す」
KR100785969B1 (ko) 2004-05-12 2007-12-14 동아제약주식회사 Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
WO2006008641A1 (en) 2004-07-16 2006-01-26 Warner-Lambert Company Llc Hair growth promoting agents
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
US20090220488A1 (en) 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
US20080139500A1 (en) 2006-12-11 2008-06-12 Isadore Elliott Goldberg Use of composite monomer or monomers, catalyst, sodium hyaluronate or hyaluronic acid, glucosamide sulfate, chondroiten sulfate or chlorides, for the treatment of osteoarthritis by intraarticular application to a hip or knee joint
PT2451964T (pt) 2009-07-10 2018-05-07 Histogen Inc Meio condiconado e composições de matriz extracelular de células cultivadas sob condições hipóxicas
SG177694A1 (en) 2009-07-16 2012-02-28 Biotime Inc Methods and compositions for in vitro and in vivo chondrogenesis
WO2011011593A1 (en) 2009-07-23 2011-01-27 Aderans Research Institute, Inc. Identity markers
US8334136B2 (en) 2009-07-24 2012-12-18 Shiseido Company, Ltd. Method for promoting hair growth or hair regeneration by maintaining or increasing expression of cell-adhesion factor
JP2013527834A (ja) 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子
WO2012151346A1 (en) 2011-05-03 2012-11-08 Dermachip Inc. Expression signatures of genes and gene networks associated with skin aging
EP2710373B1 (en) 2011-05-17 2015-06-17 Chanel Parfums Beauté Screening of large activators for preventing and/or attenuating skin ageing and/or hydrating skin
CA2853358A1 (en) * 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
JP5767591B2 (ja) 2012-01-24 2015-08-19 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 人工軟骨の製造方法
WO2013129456A1 (ja) 2012-02-29 2013-09-06 ロート製薬株式会社 線維芽細胞増殖促進能を有する組成物
WO2013144672A1 (en) 2012-03-30 2013-10-03 Société De Développement Et De Recherche Industrielle Method and kit for the classification and prognosis of wounds
EP2845910A4 (en) 2012-05-02 2015-11-25 Mitsubishi Rayon Co PROBE OR PROBE TO EVALUATE THE INFLUENCE OF ULTRAVIOLET RADIATION ON SKIN AND NUCLEIC ACID MICRO ARRAYS
WO2013185069A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mrna to non-lung target cells
ES2846789T3 (es) * 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
AU2013237760A1 (en) 2012-10-08 2014-04-24 Biotime, Inc. Differentiated progeny of clonal progenitor cell lines
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
EP3027058B1 (en) 2013-07-31 2020-07-15 Incredible Foods, Inc. Encapsulated functional food compositions
CN105636614A (zh) 2013-09-09 2016-06-01 菲格内有限责任公司 用于软骨细胞或软骨型细胞再生的基因治疗
KR101836029B1 (ko) 2014-07-07 2018-03-08 메디포스트(주) 자극된 줄기세포 배양액의 발모 촉진능 및 이의 용도
US20180148494A1 (en) 2015-01-07 2018-05-31 TheAchon Soluble fgfr3 decoys for treating skeletal growth disorders
GB201505520D0 (en) 2015-03-31 2015-05-13 Univ Lancaster Composition
KR101897340B1 (ko) * 2015-09-09 2018-09-13 중앙대학교 산학협력단 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물
CN108697812A (zh) 2016-01-14 2018-10-23 脊核细胞有限责任公司 用于软骨细胞或软骨类型细胞再生的细胞混合物
KR101900748B1 (ko) 2016-08-17 2018-09-20 (주)진셀팜 모발 성장 촉진 효과를 가지는 펩타이드, 및 이의 용도
PE20191707A1 (es) * 2017-03-06 2019-11-28 Haplnscience Inc Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1
KR20190024727A (ko) 2017-08-29 2019-03-08 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물
WO2019045451A1 (ko) 2017-08-29 2019-03-07 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물
AR118208A1 (es) 2019-02-27 2021-09-22 Haplnscience Inc Composiciones para evitar, mejorar o tratar enfermedades o síntomas relacionados con los cartílagos, que comprenden hapln1
SG11202105767YA (en) 2019-02-28 2021-06-29 Haplnscience Inc Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1
MX2021013349A (es) 2019-04-30 2022-02-03 Haplnscience Inc Composicion para la prevencion o el tratamiento de la caida del cabello que incluye hapln1.
KR102166453B1 (ko) 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
KR102284800B1 (ko) 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법

Also Published As

Publication number Publication date
BR112022015361A2 (pt) 2022-09-20
TW202130360A (zh) 2021-08-16
EP3887525A4 (en) 2022-06-22
KR102166453B1 (ko) 2020-10-15
EP3887525C0 (en) 2023-08-23
CO2022011135A2 (es) 2022-08-30
EP3887525A1 (en) 2021-10-06
US12268728B2 (en) 2025-04-08
EP3887525B1 (en) 2023-08-23
TWI792171B (zh) 2023-02-11
AU2021216358A1 (en) 2022-09-01
JP2022524899A (ja) 2022-05-11
CN115427576A (zh) 2022-12-02
PE20221663A1 (es) 2022-10-26
US20220305077A1 (en) 2022-09-29
JP7329877B2 (ja) 2023-08-21
ES2964715T3 (es) 2024-04-09
IL294952A (en) 2022-09-01
CL2022002067A1 (es) 2023-01-20
MX2022009544A (es) 2022-08-25
CN115427576B (zh) 2025-02-28
WO2021158000A1 (en) 2021-08-12
CA3166146A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
AR121243A1 (es) Composición para prevenir o tratar enfermedades pulmonares que comprenden hialuronano y proteína 1 de enlace de proteoglicano
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
NO20082448L (no) Kombinasjoner av angiopoietin-2 antagonister og VEGF-A, KDR og/eller FLT1 antagonist for behandling av cancer
BR112014019627A2 (pt) ácido nucleico compreendendo ou codificando uma haste-alça de histona e sequência poli(a) ou sinal de poliadenilação para aumento da expressão de uma proteína terapêutica codificada
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
BR112016029316A2 (pt) composição farmacêutica para uso na prevenção e/ou tratamento de doença que se desenvolve ou progride como um resultado da diminuição ou deficiência da atividade do fator de coagulação sanguínea viii e/ou fator de coagulação sanguínea ativado viii
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
BR112013023724A2 (pt) métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
BR112016024454A2 (pt) solução oftálmica aquosa e método para o tratamento da síndrome do olho seco
MX385174B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
BR112022013554A2 (pt) Métodos para tratar distúrbios do pênfigo
MX2017010763A (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
WO2011094598A3 (en) Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
EA200971059A1 (ru) Лечение и профилактика гриппа
ZA202206418B (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
BR112018015453A2 (pt) vírus atenuado da bronquite infecciosa
BR112017012799A2 (pt) combinações de composto ativo que compreendem um derivado de (tio)carboxamida e composto(s) fungicida(s).
JP2017527618A5 (es)
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BR112022024754A2 (pt) Composições e métodos para tratar covid longo
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112020019624A8 (pt) Método para tratar a hipoglicemia pós-prandial
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
MX2022004382A (es) Metodos para promover la produccion de scfa por microbiota intestinal.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal